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Abstract
Background: Our recent review of the literature uncovered eleven obesity-specific quality of life questionnaires, all
with incomplete demonstration of their measurement properties. Our objective was to validate a new self-
administered questionnaire specific to morbid obesity to be used in clinical trials. The study was carried out at the
bariatric surgery clinic of Laval Hospital, Quebec City, Canada.
Methods: This study followed our description of health-related quality of life in morbid obesity from which we
constructed the Laval Questionnaire. Its construct validity and responsiveness were tested by comparing the
baseline and changes at 1-year follow-up in 6 domain scores (symptoms, activity/mobility, personal hygiene/
clothing, emotions, social interactions, sexual life) with those of questionnaires measuring related constructs (SF-36,
Impact of Weight on Quality of Life-Lite, Rosenberg Self-Esteem Scale and Beck Depression Inventory-II).
Results: 112 patients (67 who got bariatric surgery, 45 who remained on the waiting list during the study period)
participated in this study. The analysis of the discriminative function of the questionnaire showed moderate-to-high
correlations between the scores in each domain of our instrument and the corresponding questionnaires. The
analysis of its evaluative function showed (1) significant differences in score changes between patients with
bariatric surgery and those without, and (2) moderate-to-high correlations between the changes in scores in the
new instrument and the changes in the corresponding questionnaires. Most of these correlations met the a priori
predictions we had made regarding their direction and magnitude.
Conclusion: The Laval Questionnaire is a valid measure of health-related quality of life in patients with morbid
obesity and is responsive to treatment-induced changes.
Background
Obesity is defined by a body mass index (BMI) greater
than 30 kg/m
2; when the BMI is greater than 40 kg/m
2,
obesity is morbid [1]. Morbid obesity is associated with
the onset or the deterioration of several physical health
problems, including cardiovascular diseases, type II dia-
betes, dyslipidemia, sleep apnea, respiratory failure,
osteoarthritis, infertility, and cancers of several organs
including colon, breast, prostate and endometrium [1,2].
Also, morbid obesity is often complicated by depression
and impaired quality of life [1,2]. In addition, the risk of
death of obese individuals is increased by 50 to 100% com-
pared with normal-weight individuals [3].
Treatment strategies for obesity include diet, physical
activity, behavioural therapy, pharmacotherapy and sur-
gery [1]. In the evaluation of these strategies, more
emphasis has been given to weight loss, co-morbidities
and mortality than to disease-specific quality of life [4].
Although a relationship between BMI and quality of life
impairment has been noted [4,5], this association was
weak and depended on a variety of factors including gen-
der, race, treatment-seeking status, treatment modality
and BMI, the latter explaining only about one fourth of
the variance [6,7]. Therefore, BMI or the magnitude of
weight loss after a given intervention do not necessarily
represent appropriate surrogate outcomes to quality of
life that needs to be measured directly.
Although generic instruments for measuring health-
related quality of life such as the Medical Outcome
Survey - Short Form 36 (MOS-SF-36) [8] provide use-
ful information, they are not designed to measure the
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by individuals with morbid obesity. A recent study by
Kolotkin et al. [9] found differences between weight-
related and generic measures of health-related quality
of life in a one-year weight loss trial, emphasizing the
potential value of using more than one measure in a
trial, including a disease-specific questionnaire. Our
review of the literature uncovered eleven obesity-speci-
fic quality of life questionnaires, all with incomplete
demonstration of their respective measurement proper-
ties [10]. Only three targeted morbid obesity [11-13].
Construct validity was properly studied in three ques-
tionnaires [14-16]. Demonstration of responsiveness
from independent randomized controlled trials was
available for two of the eleven questionnaires [17,18].
The interpretability of the eleven questionnaires was
limited.
We previously described the impact of morbid obesity
on the quality of life of patients seeking surgical therapy
[19]. This study identified the domains of quality of life
most frequently affected by morbid obesity from which
we constructed the Laval Questionnaire, a new self-
administered questionnaire specific to morbid obesity.
The objective of this study was to examine the validity,
reliability, responsiveness and interpretability of this new
questionnaire to be used in clinical trials.
Methods
The Laval Questionnaire
The Laval Questionnaire is a 44-item questionnaire that is
meant to be used as an evaluative instrument - that is, as a
clinical outcome in clinical trials. The Laval Questionnaire
was developed in French. The methodology used for the
construction of the questionnaire was described elsewhere
[19]. The items having the most important impact on qual-
ity of life clustered into 6 domains: (1) symptoms, 10 items;
(2) activity/mobility, 9 items; (3) personal hygiene/clothing,
5 items; (4) emotions, 11 items; (5) social interactions,
7 items and (6) sexual life, 2 items. Each domain is scored
on a 7-point Likert scale, higher scores meaning better
quality of life. The patients are asked to indicate how their
obesity affected their life over the last four weeks. Its
administration takes on average 10 minutes.
Study population
This validation study also took place in French in Laval
Hospital (Institut universitaire de cardiologie et de pneu-
mologie de Québec, Canada), the busiest Canadian baria-
tric surgery center with 500 interventions performed
yearly. Patients were selected for surgery in strict accor-
dance with the National Institutes of Health guidelines
[1]. From September 2007, two groups of consecutive
adult patients with morbid obesity awaiting bariatric sur-
gery were included. The “treatment group” consisted of
patients for whom the surgery was planned within the
next 8 weeks. The surgery consisted in a biliopancreatic
diversion with duodenal switch [20]. The “control group”
included patients waiting for surgery but not to be oper-
ated on within a year. There was no exclusion, i.e., no
limit of age or BMI was imposed and patients with co-
morbidities (such as obstructive sleep apnea, diabetes or
osteoarthritis) were also included. This study received
approval from the Ethics Committee of our institution.
Validation study
Initially, all patients completed the Laval Questionnaire
at study entry (Time 1) and, at the same time, the French
version of 4 other questionnaires measuring constructs
related to those measured by the Laval Questionnaire:
￿ MOS-SF-36 [8]: The MOS-SF-36 is a generic self-
completed questionnaire that measures 8 dimensions of
health: physical functioning, role limitation due to physi-
cal problems, role limitation due to emotional problems,
social functioning, mental health, energy/vitality, bodily
pain and general health perceptions.
￿ Impact of Weight on Quality of Life-Lite (IWQOL-
Lite) [21]: The IWQOL-Lite is a 31-item evaluative self-
completed questionnaire specific to obesity that mea-
sures 5 domains of quality of life: physical function, self-
esteem, sexual life, public distress and work.
￿ Beck Depression Inventory (BDI) [22]: The BDI is a
21-item traditional instrument that was developed speci-
f i c a l l yt oi d e n t i f yd e p r e s s i o n .I th a sb e e ne x t e n s i v e l y
used as an evaluative instrument to monitor response to
therapy in clinical trials.
￿ Rosenberg Self-Esteem Scale (SES) [23]: The SES is a
10-item self-report measure of global self-esteem. It
consists of 10 statements related to overall feelings of
self-worth or self-acceptance.
Two weeks later, assuming clinical stability over this
period of time and before any intervention, we adminis-
tered again the Laval Questionnaire to all patients in order
to examine its test-retest reliability (Time 2). The whole
set of questionnaires was again completed 1 year
(± 1 month) after surgery for the treatment group, and
one year after the initial evaluation for those still on the
waiting list (time 3). All questionnaires were self-adminis-
tered. At time 2 and time 3, the respondents remained
unaware of their previous responses.
Statistics
Baseline characteristics, questionnaires scoring and sample
size
Descriptive statistics (proportions, means and standard
deviations) were used to describe the study population at
baseline. Chi-square and t-tests were used to compare the
baseline characteristics of the “treatment” and “control”
groups when appropriate. Individual items of the Laval
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expressed as the mean score per item (ranging from 1 to
7) within each domain. The other questionnaires were
analyzed as advocated by their respective authors. We
computed that at least 45 patients were needed if moder-
ate (r = 0.50) but statistically significant correlations were
to be detected in the baseline discriminative analyses at
the 0.01 level (b error: 0.15) [24].
Reliability and internal consistency
“Test-retest reliability” was determined by correlating
t h er e s u l t so b t a i n e da tT i m e1a n dT i m e2u s i n gi n t r a -
class correlation coefficients. Internal consistency (the
extent to which different items in an instrument are
measuring the same construct) was determined for each
domain using Cronbach’s alpha statistics [25].
Discriminative properties
In this analysis, we examined the extent to which the
Laval Questionnaire can distinguish among groups of
patients. Cross-sectional construct validity was evaluated
by correlating baseline scores with other related mea-
sures, and by showing that these correlations conformed
with what one would expect if the questionnaire was
measuring what it was supposed to measure. Through-
out the regression analyses, given the multitude of com-
parisons involved, statistical significance was set at the
0.01 level.
Evaluative properties
In this analysis, we examined the extent to which the Laval
Questionnaire can capture changes in quality of life over
time (that is the responsiveness of the questionnaires).
This was primarily tested as the ability of the question-
naires to detect statistically significant differences in scores
in the patients who were treated over the study period
(Time 3 - Time 1) using paired t-tests. Also, we computed
the standardized response mean that compares the magni-
tude of change with its standard deviation [26]. The stan-
dardized response mean represents an intuitive estimate of
the “signal-to-noise ratio” defining responsiveness. Finally,
we examined the ability of the questionnaire to distinguish
between groups of patients (treated vs. untreated, i.e.,
“treatment” vs. control groups) in terms of a change in
quality of life during the study period (Time 3 - Time 1)
using unpaired t-tests. All differences (T3 - T1) were
adjusted for baseline scores. Longitudinal construct valid-
ity was also demonstrated by correlating within-subjects
changes in quality-of-life scores with within-subjects
changes in other quality-of-life indices, and by showing
that correlations of changes in different measures con-
formed with what one would expect if the questionnaire is
measuring what it is supposed to measure.
Interpretability
For an evaluative instrument, a score is interpretable
when it tells the reader whether a particular change in
score represents a significant clinical improvement or
deterioration [27]. In this analysis, we wished to esti-
mate the minimal clinically important difference
(MCID) of the new questionnaire. The MCID is defined
as the smallest difference in score which patients would
perceive as beneficial and would mandate, in the
absence of troublesome side effects and excessive cost, a
change in patients’ management [27]. To do so, we used
the regression method described by Schunemann et al.
[28]. We built linear regression models in which the
dependent variables were the differences in the Laval
Questionnaire’s domains scores, and the predictor vari-
ables were the differences in scores on the correspond-
ing IWQOL-Lite domains. We estimated MCID only
from those domains or instruments for which Pearson’s
correlation coefficients were 0.5 or greater. From the
regression equations, we calculated the score on the
Laval Questionnaire that corresponded to the MCID of
the IWQOL-Lite (7.7 to 12 on a 100-point scale) [29].
A priori predictions
We formulated ap r i o r ipredictions regarding expected
correlations between related measures. The magnitude
and direction of these correlations should conform with
what one would expect if the new instrument is measuring
what it is supposed to measure [30]. At baseline, we antici-
pated moderate-to-high correlations (0.5 ≤ r < 0.7)
between scores in each domain of the Laval Questionnaire
and the corresponding instruments. Also, we anticipated
weak-to-moderate correlations (0.3 ≤ r < 0.5) between
changes in scores in the Laval Questionnaire and changes
in the other related questionnaires. The finding that the
actual correlations meet these ap r i o r ipredictions would
strengthen inferences regarding the validity of the new
questionnaire.
Results
Patients
The demographic and clinical characteristics of the 112
(67 in the treated group and 45 in the control group)
patients who participated in the study are summarized
in Table 1. Seventy-four patients were available at 1-
year follow-up (48 in the treatment group, 26 in the
control group). The baseline characteristics of those
available vs. those unavailable at follow-up were not sta-
tistically different (data not shown).
Reliability and internal consistency
Test-retest reliability was determined from the whole
cohort (i.e., treated and control patients together, n = 90)
who completed the questionnaire two weeks apart. Test-
retest reliability was excellent, as indicated by the follow-
ing intraclass correlation coefficients in each domain:
symptoms: r = 0.93; activity/mobility: r = 0.90; personal
hygiene/clothing: r = 0.85; emotions: r = 0.90; social
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< 0.01). Cronbach’s alphas were as follows: symptoms (10
items): 0.84; activity/mobility (9 items): 0.93; personal
hygiene/clothing (5 items): 0.78; emotions (11 items):
0.90; social interactions (7 items): 0.86; and sexual life (2
items): 0.65, indicating good internal consistency for all
domains of the questionnaire.
Discriminative properties
The observed cross-sectional correlations supporting the
discriminative validity of the questionnaires are shown
in Table 2. Except for the Rosenberg Self-Esteem Scale,
we observed high correlations between the Laval Ques-
tionnaire and the other related measures. Our ap r i o r i
predictions were met in most (19/26) of them.
Evaluative properties
The ability of the Laval Questionnaire, the IWQOL-Lite
and the SF-36 to detect changes is summarized in Table
3. Results are presented as within-group differences in
the “treatment” group only. The ability to detect change
in the “treatment” group was good for all three ques-
tionnaires (all paired t tests: p < 0.001). However, the
standardized response means were generally higher with
the two obesity-specific questionnaires. Also, in examin-
ing the ability of the Laval Questionnaire to distinguish
between treated and untreated patients, we did not find
any difference between the treated and the untreated
groups at baseline (data not shown). However, at follow-
up, statistically significant differences were observed
(Table 4).
The correlations supporting the longitudinal construct
validity of the Laval Questionnaire are shown in Table
5. Overall, except for the SES, there were moderate to
high correlations between the changes in the Laval
Questionnaire and the related instruments. Our ap r i o r i
predictions were met in most (15/26) of them.
Interpretability
In the correlations between the change in the IWQOL-
Lite scores and those of the Laval Questionnaire, the
Pearson’s coefficients were all > 0.5 (Table 5). This per-
mitted our building of linear regression models in which
the dependent variable was the difference in the Laval
Questionnaire’s scores, and the independent variable
was the difference in scores on the IWQOL-Lite. The
results are presented in Table 6. The best estimate of
the MCID varied across domains and was in the range
of 0.6 to 2.0 (always on a 7-point scale).
Discussion
This validation study indicated that the Laval Question-
naire represents a valid measure of health-related quality
of life in patients with morbid obesity. It is sensitive to
treatment-induced change, an essential property for its
use in clinical trials.
We constructed the Laval Questionnaire from a study
in which patients were asked to identify what they felt
constituted the most significant items in their quality of
life and to grade their importance [19]. This method
ensured face and content validity of the new instrument.
We used the “impact method” (instead of factor analysis)
for item reduction and our clinical judgment for item
clustering [19]. Although both methods may lead to the
selection of different items, significant overlap usually
exists when they are compared. Neither of the methods
has proved superior to the other in selecting items to
describe quality of life in specific health conditions [31].
The “clinical impact method” was selected for clarity and
simplicity, and to preserve face and content validity. The
only definitive way of deciding on the optimal approach
would be to test the measurement properties of the
instruments developed using the two strategies.
In the construct validity analyses, the high correlations
between our questionnaire and the other related measures
Table 1 Clinical characteristics of the study population
Treated (n = 67) Control (n = 45) P value
Gender, male (%) 14, 21% 12, 27% 0.48
Age (years)* 45.0 (10.2) 43.6 (11.6) 0.56
Body mass index (kg/m
2)* 52.6 (8.5) 54.4 (9.7) 0.34
Co-morbidities (%)
￿ Diabetes 33 (49) 15 (33) 0.09
￿ High blood pressure 38 (57) 24 (53) 0.81
￿ Sleep apnea 31 (46) 18 (40) 0.53
￿ Osteoarthritis 33 (49) 21 (47) 0.74
Living with spouse (%) 36 (54) 29 (64) 0.29
Level of education (years)* 11.8 (2.3) 11.6 (2.3) 0.67
Currently working (%) 29 (43) 27 (60) 0.11
* Values are mean (SD)
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However, most correlations with BMI (the only anthropo-
metric measure included in our analysis) were only weak
and not significant. A first explanation is that our patients
represent a homogeneous population of patients with
morbid obesity. Since all the spectrum of obesity was not
represented in the population studied, this may have pre-
vented our finding of obesity severity as a predictor of
impaired quality of life. Another and widely accepted
explanation is that, although a relationship between the
level of BMI and quality of life impairment has been noted
[4,5], this association is weak [6,7]. Also, we interpret the
lack of correlation between the SES and the “emotions”
domain of the Laval Questionnaire as an indication that
both questionnaire measure different constructs, rather
than poor validity of either of the questionnaires.
The Laval Questionnaire proved sensitive to change in
quality of life in several ways. Statistically significant differ-
ences were observed in the patients who were submitted
to bariatric surgery (Table 3). Also, large changes in scores
we observed in treated patients, while small changes over
time were seen in the control group (Table 4). We pre-
ferred the standardized response mean to assess an instru-
ment’s responsiveness for several reasons. It represents an
intuitive estimate of the “signal-to-noise ratio” defining
responsiveness [30]. In addition, it has direct implications
for sample size determination for those planning clinical
trials. The larger the standardized response mean, the
smaller the sample size needed to demonstrate a treatment
effect.
Perhaps the most important measurement property of
a quality-of-life questionnaire used in clinical trials is its
ability to reveal a minimal clinically significant change in
a particular context. This property is referred to as “inter-
pretability” that often relies on the determination of the
MCID. Several methods have been described to deter-
mine the MCID. The “distribution-based methods” derive
from measures of the score distribution of the instrument
being explored [32]. Non-linearity of questionnaires
undermines the legitimacy of this method. Also, these
methods usually depend on the properties of the study
sample. “Anchor-based methods” compare the changes
in a studied instrument to other changes from other
instruments. Anchor-based methods require an indepen-
dent measure that is valid, that can be interpreted in
itself, and that correlates, at least moderately, with the
instrument being explored [33]. The method we used
falls in the latter category. A limitation of our analysis
comes from the fact MCID of the anchor we selected
(i.e., the IWQOL-Lite) is only available for its total score,
Table 2 Correlations* between the LAVAL Questionnaire and related instruments
LAVAL Questionnaire domains
Symptoms Activity/Mobility Personal hygiene/Clothing Emotions Social interactions Sexual life
BMI (kg/m
2) -0.14
† -0.27
‡ -0.25
‡ -0.09
† -0.26
§ -0.04
†
SF-36
￿ Physical functioning 0.67
‡ 0.58
‡
￿ Role - physical 0.75
‡ 0.59
‡
￿ Bodily pain 0.70
‡
￿ General health perception 0.57
‡
￿ Energy/vitality 0.62
‡ 0.61
‡
￿ Social functioning 0.58
‡
￿ Role - emotions 0.53
‡
￿ Mental health 0.71
‡
IWQOL-Lite
￿ Physical function 0.69
‡ 0.85
‡ 0.66
‡
￿ Self-esteem 0.80
‡ 0.77
‡
￿ Sexual life 0.61
‡
￿ Public distress 0.74
‡
SES 0.24
‡
BDI -0.77
‡
* Pearson’s coefficients of correlation; the coefficients in bold characters are those that met our a priori predictions regarding their direction and magnitude (see
text).
† Non significant correlation
‡ p ≤ 0.01
§ p < 0.05
Note: The negative coefficients of correlation obtained with the BMI and the BDI are from the higher scores on these measures indicating worse quality of life.
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regression models in which the independent variables
were the differences in scores in individual domains of
the IWQOL-Lite, we could provide only estimates of
what may constitute the MCIDs of the Laval Question-
naire’s domains. However, the determination of the
MCID should be grounded in the experience of patients,
not in statistics [33]. Only time and repeated utilization
of the Laval Questionnaire will improve our understand-
ing of its MCID.
Our study may also be considered as an independent
validation study of the IWQOL-Lite that was developed
and initially validated in a population of patients with
obesity that cannot be qualified as “morbid” (mean BMI:
36.6 km/m
2 for women and 37.2 km/m
2 for men) [21].
We found that both the IWQOL-Lite and the Laval
Questionnaire are valid and sensitive to change. Further
validation is however necessary since our study was con-
ducted in a single institution in patients who underwent
biliopancreatic diversion with duodenal switch that
Table 3 Rating of change in the Laval Questionnaire and the SF-36 after bariatric surgery (n = 48)
Questionnaires Mean (SD) SRM* 25% Median 75% Range p value
†
Laval Questionnaire
￿ Symptoms 2.1 (1.2) 1.8 1.4 2.2 3.2 -1.6 - 4.3 <0.0001
￿ Activity/Mobility 3.2 (1.6) 2.0 2.3 3.4 4.3 -0.2 - 5.6 <0.0001
￿ Personal hygiene/Clothing 3.4 (1.6) 2.1 2.0 3.4 4.8 0.6 - 6.0 <0.0001
￿ Emotions 2.3 (1.4) 1.6 1.3 2.3 3.2 -0.4 - 5.6 <0.0001
￿ Social interactions 2.8 (1.6) 1.8 1.5 2.9 3.9 -1.3 - 5.7 <0.0001
￿ Sexual life 2.5 (1.7) 1.5 1.0 2.5 4.0 -0.5 - 6.0 <0.0001
SF-36
￿ Physical functioning 48.5 (27.8) 1.7 30.0 55.0 70.0 -25.0 - 90.0 <0.0001
￿ Role - physical 50.5 (47.1) 1.1 0.0 75.0 100.0 -75.0 - 100.0 <0.0001
￿ Bodily pain 27.2 (26.4) 1.0 10.0 31.2 42.5 -34.0 - 82.0 <0.0001
￿ General health perception 33.0 (27.8) 1.2 15.8 33.0 51.1 -37.0 - 85.0 <0.0001
￿ Energy/vitality 22.4 (22.6) 1.0 10.0 22.5 43.8 -25.0 - 70.0 <0.0001
￿ Social functioning 30.2 (35.0) 0.9 0.0 25.0 62.5 -37.5 - 100.0 <0.0001
￿ Role - emotions 31.2 (56.9) 0.5 0.0 0.0 100.0 -100.0 - 100.0 0.0004
￿ Mental health 12.6 (22.4) 0.6 -4.0 12.0 28.0 -44.0 - 52.0 0.0004
IWQOL-Lite
￿ Physical Function 53.0 (24.5) 2.2 34.1 56.8 70.4 -9.1 - 100.0 <0.0001
￿ Self-Esteem 46.2 (29.8) 1.6 21.4 46.4 67.9 -3.6 - 100.0 <0.0001
￿ Sexual Life 29.6 (36.9) 0.8 0.0 25.0 51.6 -56.2 - 100.0 <0.0001
￿ Public Distress 49.9 (27.1) 1.8 25.0 55.0 71.25 -10.0 - 95.0 <0.0001
￿ Work 41.1 (30.0) 1.4 25.0 37.5 62.5 -25.0 - 100.0 <0.0001
* SRM: standardized response mean = magnitude of change/the standard deviation of change [25]. The larger the standardized response mean, the more
responsive to change the questionnaire.
† p value attached to the within-group differences in scores in the patients who were treated over the study period (paired t-tests).
Table 4 Ability of the Laval Questionnaire to distinguish treated vs. untreated patients*
A: Rating of change
(time 3 - time 1)
in the treated group
B: Rating of change
(time 3 - time 1)
in the untreated group
Treatment effect
(A - B)
P value
†
(A - B)
￿ Symptoms 2.1 (1.8 to 2.5) 0.3 (0.0 to 0.6) 1.8 (1.3 to 2.3) <0.0001
￿ Activity/Mobility 3.2 (2.7 to 3.6) 0.2 (-0.2 to 0.6) 3.0 (2.3 to 3.6) <0.0001
￿ Personal hygiene/Clothing 3.4 (2.9 to 3.8) 0.2 (-0.2 to 0.6) 3.2 (2.5 to 3.9) <0.0001
￿ Emotions 2.3 (1.9 to 2.8) 0.7 (0.3 to 1.1) 1.7 (1.0 to 2.3) <0.0001
￿ Social interactions 2.8 (2.3 to 3.2) 1.3 (0.0 to 2.7) 1.4 (0.3 to 2.6) 0.0132
￿ Sexual life 2.5 (2.0 to 3.0) 0.7 (0.2 to 1.3) 1.8 (1.0 to 2.6) <0.0001
* Results are presented as means (95% confidence intervals).
† p value attached to the group differences during the study period (unpaired t-test).
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meta-analysis of clinical trials [34].
Generic questionnaire (such as the SF-36) have also
been extensively used in obesity research. The SF-36 is
actually the most utilized and recommended question-
naire to evaluate quality of life in obesity [18,35].
Although generic questionnaires are designed to measure
all important aspects of quality of life, they are less likely
to detect change in quality of life than disease-specific
questionnaires which focus on specific areas of quality of
life. As a consequence, generic questionnaires are usually
less sensitive to change than disease-specific instruments,
a situation that we also observed in our validation study
(Table 3). We would suggest that future research
includes further validation and a better definition of the
interpretability of existing instruments, including ours.
Table 5 Correlations* in ratings of change between the LAVAL Questionnaire and related instruments
LAVAL Questionnaire domains
Symptoms Activity/Mobility Personal hygiene/Clothing Emotions Social interactions Sexual life
BMI (kg/m
2) -0.07
† -0.18
† -0.08
† -0.15
† -0.22
† -0.02
†
SF-36
￿ Physical functioning 0.70
‡ 0.55
‡
￿ Role - physical 0.61
‡ 0.54
‡†
￿ Bodily pain 0.57
‡
￿ General health perception 0.62
‡
￿ Energy/vitality 0.50
‡ 0.61
‡
￿ Social functioning 0.64
‡
￿ Role - emotions 0.43
‡
￿ Mental health 0.61
‡
IWQOL-Lite
￿ Physical function 0.73
‡ 0.87
‡ 0.74
‡
￿ Self-esteem 0.72
‡ 0.60
‡
￿ Sexual life 0.53
‡
￿ Public distress 0.74
‡
SES 0.05
†
BDI -0.71
‡
* Pearson’s coefficients of correlation; the coefficients in bold characters are those that met our a priori predictions regarding their direction and magnitude (see
text).
† Non significant correlation
‡ p < 0.01
Note: The negative coefficients of correlation obtained with the BMI and the BDI are from the higher scores on these measures indicating worse quality of life.
Table 6 Results of regression models using changes in the IWQOL-Lite to predict changes in the Laval Questionnaire
Laval
Questionnaire’s
domains
Regression equation Correlation
coefficient
(r)
D Laval Questionnaire corresponding
to DIWQOL-Lite of 7.7*
D Laval Questionnaire corresponding
to DIWQOL-Lite of 12.0*
D Symptoms 0.034 × IWQOL-Lite
Physical function + 0.38
0.73 0.64 0.78
D Activity/Mobility 0.055 × IWQOL-Lite
Physical function + 0.27
0.87 0.69 0.93
D Personal hygiene/
Clothing
0.048 × IWQOL-Lite
Physical function + 0.84
0.74 1.21 1.42
D Emotions 0.035 × IWQOL-Lite Self-
esteem + 0.73
0.72 1.00 1.15
D Social interactions 0.044 × IWQOL-Lite Public
distress + 0.64
0.74 0.97 1.16
D Sexual life 0.024 × IWQOL-Lite
Sexual Life + 1.72
0.53 1.91 2.01
* MCID of the IWQOL-Lite = 7.7 to 12 on a 100-point scale; from reference [29].
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We conclude that the Laval Questionnaire is a valid mea-
sure of health-related quality of life in patients with mor-
bid obesity and is sensitive to treatment-induced
changes. The questionnaire is available on request. We
believe that the Laval Questionnaire will be a useful tool
in research and for clinical use. Further utilization of the
questionnaire will determined the differences in score
that may be regarded as the “minimal clinically important
difference”.
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